PF-Atlas › Clinical Trials › NCT00903331
Macitentan Use in an Idiopathic Pulmonary Fibrosis Clinical Study
ACT-064992 · Phase 2
Registry ID
NCT00903331
Phase
Phase 2
Status
Completed
Drug / intervention
ACT-064992 (macitentan)
Sponsor
Actelion
Start
2009-05
Enrollment
178
Locations
53
About this trial
The AC-055B201/MUSIC study is a Phase II study, comparing one dose of ACT-064922 (macitentan) 10 mg with placebo in patients with idiopathic pulmonary fibrosis (IPF). The main study objective is to demonstrate that macitentan positively affects the forced vital capacity (FVC) in comparison with placebo in patients with idiopathic pulmonary fibrosis (IPF). The secondary objectives are to evaluate the effect of macitentan on the time to disease worsening or death in patients with IPF, and to evaluate the benefit/risk profile of macitentan in the treatment of patients with IPF.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT00903331 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.